Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)
Clinical trial NCT04476966 · COMPLETED
Trial details
- NCT number
- NCT04476966
- Sponsor
- Genuine Research Center, Egypt
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-20
- Primary completion
- 2020-03-02
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.